BioCentury | Apr 27, 2015
Politics, Policy & Law

Speed trials

...commercial GSK's involvement with Ebola started in June 2013, when it obtained rights to the cAd3-EBOZ...
BioCentury | Apr 6, 2015
Clinical News

RVSV-EBOV: Preliminary Phase II data

...of the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial showed that a single injection of cAd-EBOZ...
...Phase III portion is slated to enroll 27,000 subjects at risk of Ebola virus infection. cAd-EBOZ...
BioCentury | Apr 6, 2015
Clinical News

cAd-EBOZ: Preliminary Phase II data

...of the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial showed that a single injection of cAd-EBOZ...
...and Infectious Diseases (NIAID) sponsored the trial. GlaxoSmithKline pl c (LSE:GSK; NYSE:GSK), London, U.K. Product: cAd-EBOZ...
BioCentury | Feb 23, 2015
Clinical News

RVSV-EBOV: Phase II/III started

...trial to evaluate a single injection of cAd-EBOZ or VSV-ZEBOV in about 28,170 healthy volunteers. cAd-EBOZ...
BioCentury | Feb 23, 2015
Clinical News

cAd-EBOZ: Phase II/III started

...began the double-blind, placebo-controlled, Liberian Phase II/III PREVAIL trial to evaluate a single injection of cAd-EBOZ...
...& Co. Inc. (NYSE:MRK, Whitehouse Station, N.J.). GlaxoSmithKline pl c (LSE:GSK; NYSE:GSK), London, U.K. Product: cAd-EBOZ...
Items per page:
1 - 5 of 5